PATENT CLAIM ANALYSIS

Application Number: 16308457
Application Type: Utility
Filing Date: 2018-12
Publication Date: 2019-09
Patent Classification: ["514", "234200"]

Abstract:
A crystalline modification of triazolopyrazine derivatives binds to a hepatocyte growth factor (HGF) to activate phosphorylation, thereby significantly inhibiting the activity of c-Met kinase triggering cell proliferation, migration, and formation of new blood vessels. Therefore, the compound of the present application may be effectively used for the treatment or prevention of various hyper proliferative disorders mediated by hyper proliferation activation of cells and excessive angiogenesis.

Claim (Index 24):
A method of preparing the crystalline modification type I of  claim 1 , the method comprising:\n (a) stirring 30 to 70 mg of the compound of Chemical Formula 1 in a solvent mixture consisting of 30 to 70 mL of ethanol (EtOH) and 1 to 3 mL of ethyl acetate (EA); (b) stirring the dispersion produced in step (a) at 55 to 95\u00b0 C. for 30 to 60 minutes and cooling the dispersion to 5 to 45\u00b0 C. in an ice water bath; and (c) recovering a material precipitated in step (b) by filtration, subsequently washing the precipitated material with distilled water, and drying the washed material under reduced pressure at 20 to 45\u00b0 C.

Metadata:
- Claim Count in Document: 80.0
- Percentile: 98.0
- Lexical Diversity: 1.2807
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['13141142', '13143831', '14609137', '14158182', '13728350']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7375876549323848
- 35 USC 102 Novelty (BERT): 0.5309214697015974
- Combined Prediction Score: 0.716921036409306
- Mean Citation Score: 301.166224
- Max Citation Score: 334.4524
- Similarity Product: 236.3847910722971

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test